Catheter and method for the delivery of therapeutic agents to tissues

• US 20040204672A1
• Filed: 05/04/2004
• Published: 10/14/2004
• Est. Priority Date: 11/04/1997
• Status: Active Grant

• Current Assignee: Boston Scientific Scimed (Boston Scientific Corporation)
• Original Assignee: Boston Scientific Scimed (Boston Scientific Corporation)
• Inventors: Barry, James J., Wang, Lixiao, Palasis, Maria, Harrison, Kent D., Ellis, Louis, Hendrickson, Gary L.
• Granted Patent: US 6,953,466 B2
• Time in Patent Office: Days
• US Class Current: 604/57
• CPC Class Codes: A61B 17/3468 for implanting or removing devices, e.g. prostheses, implants, seeds, wires devices for implanting seeds A61M37/0069
• CPC Class Codes: A61B 17/3478 Endoscopic needles, e.g. for infusion biopsy needles A61B10/0233; catheters with injection needles A61M25/0067
• CPC Class Codes: A61B 2017/00247 Making holes in the wall of the heart, e.g. laser Myocardial revascularization
• CPC Class Codes: A61B 2017/320084 Irrigation sleeves
• CPC Class Codes: A61B 2018/00392 Transmyocardial revascularisation
• CPC Class Codes: A61B 2018/1425 Needle
• CPC Class Codes: A61B 90/39 Markers, e.g. radio-opaque or breast lesions markers
• CPC Class Codes: A61F 2/2493 Transmyocardial revascularisation [TMR] devices
• CPC Class Codes: A61L 2300/258 Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/64 Animal cells
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61M 2025/0004 having two or more concentrically arranged tubes for forming a concentric catheter system
• CPC Class Codes: A61M 2025/0089 Single injection needle protruding axially, i.e. along the longitudinal axis of the catheter, from the distal tip
• CPC Class Codes: A61M 25/0084 being one or more injection needles
• CPC Class Codes: A61M 37/0069 Devices for implanting pellets, e.g. markers or solid medicaments for introducing of radioactive sources for interstitial radiation therapy, i.e. brachytherapy A61N5/1027

Abstract

A method for delivering a therapeutic implant to a tissue is provided. This method includes providing an elongate catheter having a distal end including a lumen, providing a carrier including a therapeutic agent, placing the carrier including the therapeutic agent into the lumen, advancing the distal end of the catheter to the tissue, and depositing the carrier including the therapeutic agent into the tissue.

Claims

1. A method for delivering a therapeutic implant to a tissue comprising:

providing an elongate catheter having a distal end including a lumen;

providing a carrier including a therapeutic agent,

placing the carrier including the therapeutic agent into the lumen;

advancing the distal end of the catheter to the tissue, and

depositing the carrier including the therapeutic agent into the tissue.

2. The method in accordance with claim 1, wherein the tissue to be treated is ischemic heart tissue.

4. The method in accordance with claim 2, wherein the therapeutic agent includes genes effecting the production of growth factors.

5. The method in accordance with claim 2, wherein the therapeutic agent includes genetically engineered cells.

6. The method in accordance with claim 2, wherein the therapeutic agent includes healthy tissue.

7. The method in accordance with claim 2, wherein the therapeutic agent includes cells.

8. The method in accordance with claim 1, wherein the tissue includes failing heart tissue.

9. The method in accordance with claim 8, wherein the therapeutic agents are selected from the group consisting of positive inotripic, diuretics vasodilators, neurohormonal antagonists, calcium channel blockers, anti-ischemic agents, anti-arrhythmics, anticoagulants, natiruretic peptides, growth hormones, and adenosine receptor antagonists and combination thereof.

10. The method in accordance with claim 1, wherein the tissue includes heart tissue following myocardial infarction.

11. The method in accordance with claim 10, wherein the therapeutic agents are selected from the agents consisting of AKT kinases, adenylyl cylase VI, angiogenisis inducing agents and combinations thereof.

12. The method in accordance with claim 1, wherein the tissue to be treated includes cancerous tissue.

13. The method in accordance with claim 12, wherein the therapeutic agents are selected from the group consisting of cytoxic proteins, cytostatic agents, genes, anti-angiogenic molecules and combinations thereof.

3. The method in accordance with clam 2, wherein the therapeutic agent is selected from the group consisting of VEGF, FGF, PDGF, estrogen, HIF1-α

, Akt, DEL-1, angiopoietins and combinations thereof

14. A catheter for placement of an in situ implant, comprising:

an elongate shaft having a proximal end and a distal end, the shaft defining a first and a second lumen therethrough;

a first sharpened distal tip disposed at the distal end of the shaft, the first distal tip defining a lumen therethrough in fluid communication with the first lumen; and

a second sharpened distal tip disposed at the distal end of the shaft, the second distal tip defining a lumen in fluid communication with the second lumen.

15. The catheter of claim 14, further comprising a polymer mixed with a therapeutic agent is disposed in the first lumen.

16. The catheter of claim 14, further comprising a cross-linking agent disposed in the second lumen.